Kathleen Sebelius Purchases 50,000 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) Director Kathleen Sebelius acquired 50,000 shares of the company's stock in a transaction on Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. This trade represents a 121.34 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Humacyte Stock Down 2.5 %

Shares of NASDAQ HUMA traded down $0.04 during midday trading on Friday, hitting $1.53. The company had a trading volume of 4,946,430 shares, compared to its average volume of 3,555,511. The firm has a market capitalization of $221.61 million, a price-to-earnings ratio of -1.14 and a beta of 1.62. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.97. The business has a 50-day simple moving average of $2.87 and a two-hundred day simple moving average of $4.17.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analyst estimates of $0.64 million. On average, equities analysts forecast that Humacyte, Inc. will post -1.27 EPS for the current year.

Analyst Upgrades and Downgrades

HUMA has been the topic of a number of recent research reports. D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Wednesday, March 26th. Benchmark restated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Humacyte presently has a consensus rating of "Buy" and an average price target of $13.71.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Humacyte in the third quarter valued at about $596,000. Barclays PLC lifted its stake in shares of Humacyte by 177.6% during the third quarter. Barclays PLC now owns 236,742 shares of the company's stock worth $1,288,000 after purchasing an additional 151,458 shares in the last quarter. Brookstone Capital Management purchased a new stake in shares of Humacyte in the fourth quarter worth about $56,000. Finally, Wealth Effects LLC grew its stake in shares of Humacyte by 89.1% in the fourth quarter. Wealth Effects LLC now owns 121,400 shares of the company's stock valued at $613,000 after buying an additional 57,200 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.